Skip to content
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also......
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business......
On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]...
ServiceNow (NOW, daily) bounced off its 50-day moving average....
Marko Kolanovic, JPMorgan’s quant expert, sees equities as both expensive and cheap at the same time. Yes, he acknowledges stocks are priced at or near their all-time highs in absolute terms, and compared to earnings – but in relation to bonds, stocks are undervalued. And with that comparison tied directly to bond yields, which are historically low and unlikely to see gains any time soon, Kolanovic believes that stocks will act as cash magnets in 2H20.He notes that the mega-cap growth stocks are hitting new record highs again – see Apple for a prime example – and that they are benefitting from fears of a second wave of coronavirus. But Kolanovic adds that the market isn’t estimating the effect properly. While cases are rising sharply in the three of the largest states (California, Texas, Florida), death rates are remaining low. This suggests that the virus is becoming less dangerous – and...
On July 14, 2020, Wedgewood Partners released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund returned 27.13% for the second quarter of 2020. Meanwhile, the benchmark Russell 1000 Growth Index and the Russell 1000 Value Index gained 27.84% and 14.29%, respectively. You should check out Wedgewood Partners' top […]...
Akebia Therapeutics (AKBA) has announced the initiation of an investigator-sponsored study evaluating the use of vadadustat as a potential therapy to prevent and lessen the severity of acute respiratory distress syndrome (ARDS), a complication of COVID-19 infection.The randomized, double-blind, placebo-controlled study is intended to evaluate the safety and efficacy of vadadustat in up to 300 adult patients who have been hospitalized at Memorial Hermann-Texas Medical Center for hypoxemia due to COVID-19.Patients will be dosed with vadadustat or a placebo starting within 24 hours of hospital admission and continuing for up to 14 days. This study is being conducted by The University of Texas Health Science under a U.S. Food and Drug Administration Investigational New Drug (IND) application.“Right now, we can support patients with COVID-related ARDS with supplemental oxygen and different forms of ventilation, but don’t yet have effective treatments to protect their lungs and help them get better,” said one of the principal investigators,...
